Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.
An independent review report commissioned by NHS England in response to two previous commissions relating to the quality of midwifery supervision. Although statutory supervision has been removed and replaced with a new model of supervision, A-EQUIP, this review document provides
A report from Professor Sir Norman Williams looking at gross negligence manslaughter in healthcare. The review makes recommendations to support a more just and learning culture in the healthcare system. It covers: the process for investigating gross negligence manslaughter reflective
Facing the Future: Standards for children in emergency care settings document provides healthcare professionals and service planners with clear standards of care that are applicable to children in urgent and emergency care settings. They are intended to be motivating, meaningful and measurable
This clinical statement gives details about patient access to ibrutinib for chronic lymphocytic leukaemia. It states NHS is funding the cancer drug in line with NICE recommendations.
NICE impact reports review how NICE recommendations for evidence-based and cost-effective care are being used in priority areas of the health and care system, helping to improve outcomes where this is needed most.This review focus’ on the impact of Cardiovascular Disease
This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.
NICE impact reports review how NICE recommendations for evidence-based and cost-effective care are being used in priority areas of the health and care system, helping to improve outcomes where this is needed most. The National Maternity Review was commissioned by NHS England to assess maternity care
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.
This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. In February 2018, the source guidance and
Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.
Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.
Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis. This drug is for adults who have tried nonsteroidal anti-inflammatory drugs (NSAIDs), but they have not worked. Golimumab is recommended, within its marketing authorisation, as an option for treating severe non-radiographic axial
This document describes an operational definition of sepsis and supports the implementation of the NICE guidelines on the identification and treatment of sepsis.
Improving health outcomes, preventing serious illness, providing convenient, timely and cost effective care, and avoiding the unnecessary use of acute hospitals, is a shared goal across the NHS, and requires a radical re-think about how and where care is delivered,
This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them. In
NICE has assessed 2 point-of care coagulometers to help the NHS decide whether to use these products. They are called CoaguChek XS and InRatio2 PT/INR. The INRatio2 PT/INR was withdrawn from the market in October 2016 and is not currently
Evidence-based recommendations on transvaginal mesh repair of anterior or posterior vaginal wall prolapse. This involves inserting a mesh to replace tissue that has weakened and caused the pelvic organs to drop down (prolapse) into the vagina. This guidance replaces NICE interventional